|Security||THCBF / THC Biomed International Ltd. (87243W103)|
|Industry||Cannabis and Medical Marijuana Dispensaries|
Institutional Stock Ownership and Shareholders
THC Biomed International Ltd. (OTC:THCBF) has 0 institutional investors and shareholders that have
filed 13D/G or 13F forms with the Securities Exchange Commission (SEC).
Largest shareholders include
THC Biomed International Ltd. (OTC:THCBF) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.
2017-12-25 - Asif
The Company’s principal business is the production and sale of medical marijuana through THC BioMed Ltd. which is licensed to produce and sell medical marijuana under the provisions of the Access to Cannabis for Medical Purposes Regulations (“ACMPR”). The Company also conducts research and development of the products and services related to cannabis for medical purposes. At the close of business on July 31, 2017, THC BioMed Ltd. and THC Meds Inc. were amalgamated and the name THC BioMed Ltd. was retained. History of business On February 18, 2016, THC BioMed Ltd. received its license to grow medical marijuana. On May 24, 2016 the Company’s license was amended to include the production of fresh marijuana, cannabis oil, and cannabis resin. On September 26, 2016, the Company announced that it signed a Letter of Intent to purchase 100% of Clone Shipper LLC, a US based company specializing in the packaging products used to transport live plants, for US$1,000,000. This is ...
Related News Stories
Your license and viewing of our content is subject to the disclosures contained after this article. (5-4)
Your license and viewing of our content is subject to the disclosures contained after this article. (18-0)
as of ET